Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Protagonist Therapeutics, Inc. - Common Stock
(NQ:
PTGX
)
91.55
+0.17 (+0.19%)
Streaming Delayed Price
Updated: 12:14 PM EST, Dec 11, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Protagonist Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
Next >
Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice
November 27, 2025
Via
ACCESS Newswire
Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 06, 2025
Via
ACCESS Newswire
Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH Meeting
November 03, 2025
Via
ACCESS Newswire
Protagonist Announces New Icotrokinra Data in Ulcerative Colitis and Plaque Psoriasis Presented at Two Recent Medical Conferences
October 27, 2025
Via
ACCESS Newswire
Big Pharma Just Put Peptides Back on the Map – Which Players Are Still Under the Radar?
October 20, 2025
Via
AB Newswire
Protagonist Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
February 21, 2025
Via
ACCESS Newswire
Protagonist Announces New Icotrokinra Data in Ulcerative Colitis Showing Potential for a Standout Combination of Therapeutic Benefit and a Favorable Safety Profile in Once-daily Pill
October 07, 2025
Via
ACCESS Newswire
Protagonist Announces Presentations of Clinical Data with Icotrokinra in Plaque Psoriasis and Preclinical Data with PN-881 at the EADV 2025 Congress
September 17, 2025
Via
ACCESS Newswire
Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025
September 15, 2025
Via
ACCESS Newswire
Protagonist Announces Icotrokinra Application for Approval in Plaque Psoriasis Submitted to the European Medicines Agency
September 11, 2025
Via
ACCESS Newswire
Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in September 2025
August 26, 2025
Via
ACCESS Newswire
Rusfertide Receives Breakthrough Therapy Designation for Treatment of Erythrocytosis in Patients with Polycythemia Vera
August 25, 2025
Via
ACCESS Newswire
Protagonist Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 06, 2025
Via
ACCESS Newswire
Protagonist Announces Submission of NDA for First Icotrokinra U.S. FDA Approval Aiming to Revolutionize Treatment Paradigm for Adults and Adolescents with Plaque Psoriasis
July 21, 2025
Via
ACCESS Newswire
Protagonist Announces Nomination of PN-477, an Oral and Injectable GLP-1R, GIPR, and GCGR Triple Agonist Peptide Development Candidate for Obesity
June 30, 2025
Via
ACCESS Newswire
Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate
June 26, 2025
Via
ACCESS Newswire
Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera
June 01, 2025
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2025
May 21, 2025
Via
ACCESS Newswire
Protagonist Announces Icotrokinra Phase 3 Data on Difficult-to-Treat Scalp and Genital Psoriasis and Preclinical Data on PN-881 Presented at the Society for Investigative Dermatology Annual Meeting
May 09, 2025
Via
ACCESS Newswire
Protagonist Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 06, 2025
Via
ACCESS Newswire
Protagonist Therapeutics Announces Plenary Presentation on VERIFY Phase 3 Study with Rusfertide at ASCO 2025
April 23, 2025
Via
ACCESS Newswire
Protagonist Therapeutics Reports Granting of Inducement Award
April 16, 2025
Via
ACCESS Newswire
Icotrokinra Results Show 75% of Adolescents with Plaque Psoriasis Achieved Completely Clear Skin and Demonstrate Favorable Safety Profile with a Once Daily Pill
April 10, 2025
Via
ACCESS Newswire
Protagonist Therapeutics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025
March 18, 2025
Via
ACCESS Newswire
Protagonist Reports Positive Top Line Results From Phase 2b Study of Icotrokinra Showing Potential to Transform the Treatment Paradigm for Patients With Ulcerative Colitis
March 10, 2025
Via
ACCESS Newswire
Icotrokinra Clinical Study Results Demonstrate Its Potential to Shift Treatment Paradigm and Set a New Standard for Treatment in Plaque Psoriasis
March 08, 2025
Via
ACCESS Newswire
Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera
March 03, 2025
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Protagonist to Host Investor Event with KOL Insights on Polycythemia Vera (PV) and the Hepcidin Mimetic Rusfertide in New York on February 6, 2025
January 29, 2025
Via
ACCESS Newswire
Protagonist Therapeutics Reports Granting of Inducement Awards
January 06, 2025
Via
ACCESSWIRE
Protagonist Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025
December 19, 2024
Via
ACCESSWIRE
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
